July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
Volumetric characteristics quantification of choroidal neovascularization secondary to exudative age-related macular degeneration in swept source OCT angiographyduring the monthly loading dose of anti-VEGF therapy.
Author Affiliations & Notes
  • Ala'a EL AMEEN
    Ophtalmology, Centre Hospitalier Intercommunal de Creteil, Creteil, France
  • Luis De Sisternes
    Carl Zeiss Meditec, Inc., California, United States
  • Oudy Semoun
    Ophtalmology, Centre Hospitalier Intercommunal de Creteil, Creteil, France
  • ALEXANDRA MOUALLEM-BEZIERE
    Ophtalmology, Centre Hospitalier Intercommunal de Creteil, Creteil, France
  • Eric H Souied
    Ophtalmology, Centre Hospitalier Intercommunal de Creteil, Creteil, France
  • Footnotes
    Commercial Relationships   Ala'a EL AMEEN, None; Luis De Sisternes, None; Oudy Semoun, None; ALEXANDRA MOUALLEM-BEZIERE, None; Eric Souied, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 3472. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Ala'a EL AMEEN, Luis De Sisternes, Oudy Semoun, ALEXANDRA MOUALLEM-BEZIERE, Eric H Souied; Volumetric characteristics quantification of choroidal neovascularization secondary to exudative age-related macular degeneration in swept source OCT angiographyduring the monthly loading dose of anti-VEGF therapy.. Invest. Ophthalmol. Vis. Sci. 2019;60(9):3472. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To use swept-source optical coherence tomography angiography (SS-OCTA) to monitor the 3 dimensional structural modification and short-term blood flow changes of choroidal neovascularization (CNV)in treatment-naïve eyes with age-related macular degeneration during the monthly loading dose of anti-VEGF therapy.

Methods : 5 treatment-naive patients were evaluatedevery week with SS-OCTA during anti-VEGF loading dose. Macular spectral-domain OCT (SD-OCT,Heidelberg Engineering; Vista, CA) were performed at each visit and retinal SS-OCTA volumes of either a 3x3mm or a 6x6mm field of view were collected using a PLEX® Elite 9000 with AngioPlex OCT Angiography (ZEISS, Dublin, CA). The CNV total volume, area, vessel perfusion (total area of perfused vasculature), vessel density (total length of perfused vasculature)and invasiveness (intrusion within the retina) were measured and compared to exudative signs seen on SD-OCT. CNV invasiveness was characterized by the “invasiveness volume rate” (ratio between the CNV volume and the total retina volume), “CNV maximum height”, “maximum height rate” (maximum value of theratio between CNV thickness and retina thickness)and “mean height rate”(average value of the ratio between CNV thickness and retina thickness).

Results : Preliminary results of the 3 first patients showed rapid decrease of the mean CNV volume (30%) and the mean CNV area (24%) one week after anti-VEGF therapy, followed from the 2ndweek by a gradual increase until a return to their initial valueat the next intravitreal injection. All invasiveness parameters showed a decrease from the injection then remained stable until return to the initial state one month after.Conversely vessel density and perfusion did not show a significant difference during treatment. On SD-OCT, exudative signs reappeared from the 3rdweek after anti-VEGF treatment.

Conclusions : The close follow-up of CNV on OCTA reveals a very rapid decrease in CNV volume and CNV area after anti-VEGF intravitreal injection within treatment cycles.
Quantitative changes, taking into account the whole volume of the CNV, appear before the exudative signs on SD-OCT suggesting a prediction of CNV activity and the possibility to better optimize the anti-angiogenic treatment.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×